From Drugs Controller General of India
Astrazeneca Pharma India has received Import and Market permission in Form 45 (Marketing Authorization- Additional Indication) from the Drugs Controller General of India for Osimertinib Tablet 40 mg and 80 mg (TagrissoTM) indicated as first-line treatment of patients with locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) whose tumours have Epidermal Growth Factor Receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitutions mutations.The receipt of this Import and Market permission paves way for the launch of Osimertinib Tablets (TagrissoTM) for first-line treatment of patients in India, subject to the receipt of other related statutory approvals and licenses.
The first-line use of Osimertinib offers potential new standard of care.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
